Dabigatran  ||| S:0 E:11 ||| NNP
as  ||| S:11 E:14 ||| IN
an  ||| S:14 E:17 ||| DT
alternative  ||| S:17 E:29 ||| NN
to  ||| S:29 E:32 ||| TO
warfarin  ||| S:32 E:41 ||| VB
for  ||| S:41 E:45 ||| IN
the  ||| S:45 E:49 ||| DT
prevention  ||| S:49 E:60 ||| NN
of  ||| S:60 E:63 ||| IN
thromboembolism  ||| S:63 E:79 ||| FW
in  ||| S:79 E:82 ||| FW
atrial  ||| S:82 E:89 ||| FW
fibrillation  ||| S:89 E:102 ||| FW
Atrial  ||| S:102 E:109 ||| FW
fibrillation  ||| S:109 E:122 ||| FW
( ||| S:122 E:123 ||| -LRB-
AF ||| S:123 E:125 ||| NNP
)  ||| S:125 E:127 ||| -RRB-
is  ||| S:127 E:130 ||| VBZ
an  ||| S:130 E:133 ||| DT
independent  ||| S:133 E:145 ||| JJ
major  ||| S:145 E:151 ||| JJ
risk  ||| S:151 E:156 ||| NN
factor  ||| S:156 E:163 ||| NN
for  ||| S:163 E:167 ||| IN
stroke ||| S:167 E:173 ||| NN
,  ||| S:173 E:175 ||| ,
and  ||| S:175 E:179 ||| CC
antithrombotic  ||| S:179 E:194 ||| JJ
therapy  ||| S:194 E:202 ||| NN
is  ||| S:202 E:205 ||| VBZ
here  ||| S:205 E:210 ||| RB
recommended  ||| S:210 E:222 ||| VBN
according  ||| S:222 E:232 ||| VBG
to  ||| S:232 E:235 ||| TO
stratification  ||| S:235 E:250 ||| VB
of  ||| S:250 E:253 ||| IN
the  ||| S:253 E:257 ||| DT
patient ||| S:257 E:264 ||| NN
's  ||| S:264 E:267 ||| POS
thromboembolic  ||| S:267 E:282 ||| NN
and  ||| S:282 E:286 ||| CC
hemorrhagic  ||| S:286 E:298 ||| JJ
risks ||| S:298 E:303 ||| NNS
.  ||| S:303 E:305 ||| .
Recent  ||| S:305 E:312 ||| JJ
evidence  ||| S:312 E:321 ||| NN
is  ||| S:321 E:324 ||| VBZ
leading  ||| S:324 E:332 ||| VBG
to  ||| S:332 E:335 ||| TO
the  ||| S:335 E:339 ||| DT
replacement  ||| S:339 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
vitamin  ||| S:354 E:362 ||| JJ
K  ||| S:362 E:364 ||| NN
antagonists ||| S:364 E:375 ||| NNS
,  ||| S:375 E:377 ||| ,
the  ||| S:377 E:381 ||| DT
efficacy  ||| S:381 E:390 ||| NN
of  ||| S:390 E:393 ||| IN
which  ||| S:393 E:399 ||| WDT
in  ||| S:399 E:402 ||| IN
preventing  ||| S:402 E:413 ||| VBG
stroke  ||| S:413 E:420 ||| NN
in  ||| S:420 E:423 ||| IN
AF  ||| S:423 E:426 ||| NNP
is  ||| S:426 E:429 ||| VBZ
well  ||| S:429 E:434 ||| RB
established ||| S:434 E:445 ||| VBN
,  ||| S:445 E:447 ||| ,
with  ||| S:447 E:452 ||| IN
better  ||| S:452 E:459 ||| JJR
tolerated  ||| S:459 E:469 ||| NNS
and  ||| S:469 E:473 ||| CC
more  ||| S:473 E:478 ||| RBR
manageable  ||| S:478 E:489 ||| JJ
new  ||| S:489 E:493 ||| JJ
anticoagulant  ||| S:493 E:507 ||| JJ
drugs ||| S:507 E:512 ||| NNS
,  ||| S:512 E:514 ||| ,
with  ||| S:514 E:519 ||| IN
a  ||| S:519 E:521 ||| DT
lower  ||| S:521 E:527 ||| JJR
risk  ||| S:527 E:532 ||| NN
of  ||| S:532 E:535 ||| IN
intracranial  ||| S:535 E:548 ||| JJ
bleeding ||| S:548 E:556 ||| NN
,  ||| S:556 E:558 ||| ,
no  ||| S:558 E:561 ||| DT
clear  ||| S:561 E:567 ||| JJ
interactions  ||| S:567 E:580 ||| NNS
with  ||| S:580 E:585 ||| IN
food ||| S:585 E:589 ||| NN
,  ||| S:589 E:591 ||| ,
fewer  ||| S:591 E:597 ||| JJR
interactions  ||| S:597 E:610 ||| NNS
with  ||| S:610 E:615 ||| IN
medications ||| S:615 E:626 ||| NN
,  ||| S:626 E:628 ||| ,
and  ||| S:628 E:632 ||| CC
no  ||| S:632 E:635 ||| DT
need  ||| S:635 E:640 ||| NN
for  ||| S:640 E:644 ||| IN
frequent  ||| S:644 E:653 ||| JJ
laboratory  ||| S:653 E:664 ||| NN
monitoring  ||| S:664 E:675 ||| NN
and  ||| S:675 E:679 ||| CC
dose  ||| S:679 E:684 ||| NN
adjustments ||| S:684 E:695 ||| NNS
.  ||| S:695 E:697 ||| .
Among  ||| S:697 E:703 ||| IN
new  ||| S:703 E:707 ||| JJ
anticoagulants ||| S:707 E:721 ||| NN
,  ||| S:721 E:723 ||| ,
dabigatran  ||| S:723 E:734 ||| JJ
etexilate  ||| S:734 E:744 ||| NN
is  ||| S:744 E:747 ||| VBZ
a  ||| S:747 E:749 ||| DT
direct ||| S:749 E:755 ||| JJ
,  ||| S:755 E:757 ||| ,
competitive  ||| S:757 E:769 ||| JJ
inhibitor  ||| S:769 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
thrombin ||| S:782 E:790 ||| NN
.  ||| S:790 E:792 ||| .
It  ||| S:792 E:795 ||| PRP
was  ||| S:795 E:799 ||| VBD
evaluated  ||| S:799 E:809 ||| VBN
for  ||| S:809 E:813 ||| IN
patients  ||| S:813 E:822 ||| NNS
with  ||| S:822 E:827 ||| IN
AF  ||| S:827 E:830 ||| NNP
in  ||| S:830 E:833 ||| IN
the  ||| S:833 E:837 ||| DT
RE-LY  ||| S:837 E:843 ||| JJ
trial ||| S:843 E:848 ||| NN
,  ||| S:848 E:850 ||| ,
showing  ||| S:850 E:858 ||| VBG
lower  ||| S:858 E:864 ||| JJR
rates  ||| S:864 E:870 ||| NNS
of  ||| S:870 E:873 ||| IN
stroke  ||| S:873 E:880 ||| NN
and  ||| S:880 E:884 ||| CC
systemic  ||| S:884 E:893 ||| JJ
embolism  ||| S:893 E:902 ||| NN
at  ||| S:902 E:905 ||| IN
a  ||| S:905 E:907 ||| DT
dose  ||| S:907 E:912 ||| NN
of  ||| S:912 E:915 ||| IN
150  ||| S:915 E:919 ||| CD
mg  ||| S:919 E:922 ||| NNS
twice  ||| S:922 E:928 ||| RB
daily  ||| S:928 E:934 ||| JJ
with  ||| S:934 E:939 ||| IN
similar  ||| S:939 E:947 ||| JJ
rates  ||| S:947 E:953 ||| NNS
of  ||| S:953 E:956 ||| IN
major  ||| S:956 E:962 ||| JJ
hemorrhage  ||| S:962 E:973 ||| NNS
compared  ||| S:973 E:982 ||| VBN
with  ||| S:982 E:987 ||| IN
warfarin ||| S:987 E:995 ||| NNS
;  ||| S:995 E:997 ||| :
and  ||| S:997 E:1001 ||| CC
non-inferiority  ||| S:1001 E:1017 ||| JJ
compared  ||| S:1017 E:1026 ||| VBN
with  ||| S:1026 E:1031 ||| IN
warfarin  ||| S:1031 E:1040 ||| NN
for  ||| S:1040 E:1044 ||| IN
the  ||| S:1044 E:1048 ||| DT
prevention  ||| S:1048 E:1059 ||| NN
of  ||| S:1059 E:1062 ||| IN
stroke  ||| S:1062 E:1069 ||| NN
and  ||| S:1069 E:1073 ||| CC
systemic  ||| S:1073 E:1082 ||| JJ
embolism  ||| S:1082 E:1091 ||| NN
at  ||| S:1091 E:1094 ||| IN
a  ||| S:1094 E:1096 ||| DT
dose  ||| S:1096 E:1101 ||| NN
of  ||| S:1101 E:1104 ||| IN
110  ||| S:1104 E:1108 ||| CD
mg  ||| S:1108 E:1111 ||| NNS
twice  ||| S:1111 E:1117 ||| RB
daily ||| S:1117 E:1122 ||| RB
,  ||| S:1122 E:1124 ||| ,
with  ||| S:1124 E:1129 ||| IN
lower  ||| S:1129 E:1135 ||| JJR
rates  ||| S:1135 E:1141 ||| NNS
of  ||| S:1141 E:1144 ||| IN
major  ||| S:1144 E:1150 ||| JJ
bleeding ||| S:1150 E:1158 ||| NN
.  ||| S:1158 E:1160 ||| .
Beside  ||| S:1160 E:1167 ||| IN
dabigatran ||| S:1167 E:1177 ||| NN
,  ||| S:1177 E:1179 ||| ,
oral  ||| S:1179 E:1184 ||| JJ
factor  ||| S:1184 E:1191 ||| NN
Xa  ||| S:1191 E:1194 ||| NNP
inhibitors  ||| S:1194 E:1205 ||| NNS
are  ||| S:1205 E:1209 ||| VBP
also  ||| S:1209 E:1214 ||| RB
emerging  ||| S:1214 E:1223 ||| VBG
for  ||| S:1223 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
prevention  ||| S:1231 E:1242 ||| NN
of  ||| S:1242 E:1245 ||| IN
thromboembolic  ||| S:1245 E:1260 ||| JJ
events  ||| S:1260 E:1267 ||| NNS
in  ||| S:1267 E:1270 ||| IN
AF ||| S:1270 E:1272 ||| NNP
.  ||| S:1272 E:1274 ||| .
Despite  ||| S:1274 E:1282 ||| IN
the  ||| S:1282 E:1286 ||| DT
obvious  ||| S:1286 E:1294 ||| JJ
advantages  ||| S:1294 E:1305 ||| NNS
of  ||| S:1305 E:1308 ||| IN
these  ||| S:1308 E:1314 ||| DT
new  ||| S:1314 E:1318 ||| JJ
oral  ||| S:1318 E:1323 ||| JJ
anticoagulants  ||| S:1323 E:1338 ||| NN
over  ||| S:1338 E:1343 ||| IN
vitamin  ||| S:1343 E:1351 ||| JJ
K  ||| S:1351 E:1353 ||| NN
antagonists ||| S:1353 E:1364 ||| NNS
,  ||| S:1364 E:1366 ||| ,
further  ||| S:1366 E:1374 ||| JJ
information  ||| S:1374 E:1386 ||| NN
is  ||| S:1386 E:1389 ||| VBZ
still  ||| S:1389 E:1395 ||| RB
needed  ||| S:1395 E:1402 ||| VBN
on  ||| S:1402 E:1405 ||| IN
how  ||| S:1405 E:1409 ||| WRB
to  ||| S:1409 E:1412 ||| TO
prioritize  ||| S:1412 E:1423 ||| VB
the  ||| S:1423 E:1427 ||| DT
patients  ||| S:1427 E:1436 ||| NNS
deriving  ||| S:1436 E:1445 ||| VBG
the  ||| S:1445 E:1449 ||| DT
greatest  ||| S:1449 E:1458 ||| JJS
benefit  ||| S:1458 E:1466 ||| NN
from  ||| S:1466 E:1471 ||| IN
these  ||| S:1471 E:1477 ||| DT
novel  ||| S:1477 E:1483 ||| NN
agents  ||| S:1483 E:1490 ||| NNS
on  ||| S:1490 E:1493 ||| IN
the  ||| S:1493 E:1497 ||| DT
basis  ||| S:1497 E:1503 ||| NN
of  ||| S:1503 E:1506 ||| IN
patient  ||| S:1506 E:1514 ||| JJ
characteristics  ||| S:1514 E:1530 ||| NNS
or  ||| S:1530 E:1533 ||| CC
drug  ||| S:1533 E:1538 ||| NN
pharmacokinetics ||| S:1538 E:1554 ||| NN
.  ||| S:1554 E:1556 ||| .
There  ||| S:1556 E:1562 ||| EX
is  ||| S:1562 E:1565 ||| VBZ
also  ||| S:1565 E:1570 ||| RB
a  ||| S:1570 E:1572 ||| DT
need  ||| S:1572 E:1577 ||| NN
for  ||| S:1577 E:1581 ||| IN
assessing  ||| S:1581 E:1591 ||| VBG
their  ||| S:1591 E:1597 ||| PRP$
long-term  ||| S:1597 E:1607 ||| JJ
efficacy  ||| S:1607 E:1616 ||| NN
and  ||| S:1616 E:1620 ||| CC
safety  ||| S:1620 E:1627 ||| NN
over  ||| S:1627 E:1632 ||| IN
decades  ||| S:1632 E:1640 ||| NNS
in  ||| S:1640 E:1643 ||| IN
the  ||| S:1643 E:1647 ||| DT
real-world  ||| S:1647 E:1658 ||| JJ
setting ||| S:1658 E:1665 ||| NN
.  ||| S:1665 E:1667 ||| .
